Singular Genomics Systems, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
DEFA14A: Singular Genomics Faces Lawsuits Over Merger Disclosures, Voluntarily Supplements Proxy Statement
Singular Genomics Systems, Inc. is supplementing its proxy statement related to its merger with a subsidiary of Deerfield Private Design Fund IV, L.P. following lawsuits alleging misleading omissions.
Singular Genomics Systems, Inc. is set to be acquired by Deerfield Private Design Fund IV for $20.00 per share in cash, representing a 253% premium over the unaffected stock price.
Singular Genomics Systems, Inc. has entered into a definitive agreement to be acquired by an affiliate of Deerfield Management Company, L.P. for $20.00 per share in cash.
Singular Genomics Systems, Inc. will hold its annual meeting of stockholders virtually on May 29, 2024, to vote on the election of directors, ratification of the company's independent auditor, and a potential reverse stock split.
DEF 14A: Singular Genomics Seeks Stockholder Approval for Reverse Stock Split and Director Elections
Singular Genomics Systems, Inc. is holding its 2024 Annual Meeting of Stockholders on May 29, 2024, to vote on director elections, ratification of the accounting firm, and a potential reverse stock split.